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Validation of the Distress Thermometer in a Mexican population with brain
tumors: A Diagnostic Accuracy Study
Abstract
Objective: Mental health in cancer patients must be addressed. This study's main objective was to
evaluate the sensitivity and specificity of the DT in a population of patients with brain tumors and
determine the optimal cut-off point for the DT. Methods: We performed a cross-sectional study at the
National Institute of Neurology and Neurosurgery in Mexico City, in a cohort of 110 patients. Results: Of
the 108 participants with brain tumors that were included in the analysis (2 patients excluded by
incomplete DT), 40 had gliomas, 31 had pituitary adenomas, 21 had meningiomas, and 16 had other types
of tumors. Mean distress as measured by DT was 5.37 (SD=3), and the mean total problem list score was
21 (SD=9.14), with the most common subtype being physical problems (mean 7.7, SD=4.5) and emotional
problems (mean 3.8, SD=1.9). HADS-T score mean was 13.7 (SD=7.3), with the mean HADS-D and HADSA subsets being 5.8 (SD=4) and 7.85 (SD=4.4) respectively. A Receiver Operating Curve (ROC) analysis
was performed to determine the optimal cut-off point of the DT in our population. We obtained an Area
Under the Curve (AUC) of 0.71 (CI95%=0.61-0.81, p
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Abstract
Objective: Mental health in cancer patients must be addressed. This study's main objective was to evaluate the
sensitivity and speciﬁcity of the DT in a population of patients with brain tumors and determine the optimal cut-off
point for the DT.
Methods: We performed a cross-sectional study at the National Institute of Neurology and Neurosurgery in Mexico
City, in a cohort of 110 patients.
Results: Of the 108 participants with brain tumors that were included in the analysis (2 patients excluded by incomplete
DT), 40 had gliomas, 31 had pituitary adenomas, 21 had meningiomas, and 16 had other types of tumors. Mean distress
as measured by DT was 5.37 (SD ¼ 3), and the mean total problem list score was 21 (SD ¼ 9.14), with the most common
subtype being physical problems (mean 7.7, SD ¼ 4.5) and emotional problems (mean 3.8, SD ¼ 1.9). HADS-T score
mean was 13.7 (SD ¼ 7.3), with the mean HADS-D and HADS-A subsets being 5.8 (SD ¼ 4) and 7.85 (SD ¼ 4.4)
respectively. A Receiver Operating Curve (ROC) analysis was performed to determine the optimal cut-off point of the
DT in our population. We obtained an Area Under the Curve (AUC) of 0.71 (CI95% ¼ 0.61e0.81, p < 0.001) comparing
against HADS-T score; an AUC of 0.726 (CI95% ¼ 0.62e0.82, p < 0.001) comparing against the HADS-A subset, and an
AUC of 0.63 (CI95% ¼ 0.53e0.74, p ¼ 0.021) when comparing against HADS-D subset.
Conclusions: The DT is a psycho-oncologic screening tool applied to cancer patients to screen for emotional distress. We
used it in patients with intracranial tumors and found six as a good cut-off point.
Keywords: Depression, Anxiety, Distress thermometer, Brain tumors, Cancer, STARD, Sensitivity, Speciﬁcity

1. Introduction

T

hroughout the world, cancer incidence is
growing every year, therefore, arising
problems in this group of patients must be
addressed, including mental health. The National
Comprehensive Cancer Network (NCCN) estimates that 38.4% of the population will develop
cancer in their lifetime [1]. Neurological cancers
are the 15th most common and have the 10th

highest mortality rate in the United States [2]. In
Mexico, it is the 17th most common and the 13th
deadliest type of cancer [3]. These patients have a
higher rate of mental health pathology; therefore,
it must be screened and managed appropriately
[4].
Cancer patients are at increased risk of mental
health disorders, including depression and anxiety,
which are commonly under-recognized comorbidities. These emotional complications decrease the
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quality of life and can affect the prognosis of cancer
patients. Overall, there is a 3-fold risk of having
depression in a cancer patient than the general
population [5]. Cancer is a pathology that carries a
high risk of suicide, which is why the detection of
depression and mental health issues is of great
importance. According to the current NCCN
guidelines screening for distress and emotional
complications is required for all patients with cancer
[4].
The Distress Thermometer (DT) is a psychooncologic screening tool developed by the NCCN
initially published in 1998 [6]. This tool can be used
in every cancer patient to screen for emotional
distress; it is accompanied by a Problem List (PL)
checklist for the patient to ﬁll out the sources of that
distress. This tool has been translated to over 21
languages and is broadly used all around the world.
There is no paper validating the DT for brain tumors. The closest paper translated and validated
this tool in various types of cancer, comparing it to
the Hospital Anxiety and Depression Scale (HADS);
they found a cut-off point of 4 to have the best
sensitivity [7]. Several cut-off points are used globally depending on the type of cancer; a recent metaanalysis showed that most cut-off points range from
3 to 7 in different types of cancer (breast, lymphoma,
prostate, colorectal among others) [8]. Few studies
have analyzed the DT in patients with brain tumors,
showing cut-offs varying from 4 to 6, but none in a
Latin-American population [9,10].
The main objective of this study was to evaluate
the sensitivity and speciﬁcity of the DT in a population of patients with brain tumors in Mexico and
determine the optimal cut-off point for the DT
comparing it to the HADS, which can detect
depression and anxiety, for its validation. Our central hypothesis was that the DT in our population
would behave like other reported studies, with an
optimal cut-off point between 4 and 6 and a minimum sensitivity of 75%, for screening purposes.

2. Methods
We performed a cross-sectional study in the National Institute of Neurology and Neurosurgery in
Mexico City between July to September 2019.
The study's main goal was to validate the NCCN
Distress Thermometer in a population of patients
with brain tumors of any kind. This study was
modeled and performed after the STARD guidelines
for reporting diagnostic accuracy studies [11]. The
study was approved by the research and ethics
Institutional Review Board of the hospital before
starting the study.
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Abbreviation list
DT
PL:
HADS
AUC
SD
ROC:
NCCN
STARD
PHQ9
TP
TN
FP
FN
PPV
NPV
LR
LR

Distress Thermometer
Problem List
Hospital Anxiety Depression Scale
Area Under the Curve
Standard Deviation
Receiver Operating Characteristic
National Comprehensive Cancer Network
Standards for Reporting of Diagnostic Accuracy
Studies
Patient Health Questionnaire
True Positive
True Negative
False Positive
False Negative
Positive Predictive Value
Negative Predictive Value
Positive Likelihood Ratio
Negative Likelihood Ratio

Patients were recruited in the outpatient clinic and
invited to participate in the study. We used convenience sampling to recruit 110 patients from the
outpatient neurosurgery clinic in the hospital. Inclusion criteria were age >18 years, patients with a
conﬁrmed histological diagnosis of a brain tumor,
the capacity to ﬁll-out self-application forms, and
patients who give informed consent to participate in
the study. Patients with previous or current psychiatric disorders were excluded as well as those
with missing data. Data collection was planned
before both the DT and HADS were performed.
Standardized protocols of data collection were
applied to homogenize data and prevent data loss.
Both tests were applied on the same visit. The ﬂow
of patients in the study is shown in Fig. 1.
2.1. The NCCN distress thermometer
The DT is a 1-item rapid-screening tool for
detecting distress in cancer patients; the patients are
asked to ﬁll out their distress (in the past week) in a
visual thermometer scale ranging from 0 to 10 (10
being the highest level of distress). The Thermometer is accompanied by a Problem List (PL), where
patients need to state whether they had or not any of
them (during the past week). The PL consists of 36
items grouped in different categories to establish
the source of the patient's distress. The patients selfﬁlled a printed out form of the DT/PL form provided
in the neurosurgical follow-up consultation. The
physician explained the instructions and answered
any questions that arose during this period. The DT
version used in the study was the Spanish translation done by Almanza-Mu~
noz et al. [7].
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Fig. 1. STARD Flow Diagram showing the ﬂow of patients in our study, including the index and the reference standard used in the study.

The Hospital Anxiety and Depression Scale
(HADS) is a self-applied 14-item patient questionnaire to screen for mood disorders in the clinical
setting. It is the most studied and validated tool, and
it has been validated for its use in cancer patients
[12]. It consists of two subsets of questions, one for
detecting anxiety (HADS-A) and another for
detecting depression (HADS-D); it is graded on a
numerical scale, each subset graded from 0 to 21, for
a total score (HADS-T) ranging from 0 to 42. The
cut-off points for HADS-A and HADS D are>7, and
for the HADS-T, it is > 14 for a positive test. Patients
were referred to the mental health clinic either if
they had a subset or a total score positive test.
HADS was chosen to be the reference standard for
the study from other choices, like the Patient Health
Questionnaire (PHQ9) because it assesses both
anxiety and depression combined in the same test
[13] its reliability in various clinical settings and
pathologies. A research fellow blindly reviewed
answers to the DT/PL and the HADS concerning the
personal information and the patient's demographic
baseline characteristics. The DT and HADS were
applied to the participants the same day in the clinic
without time in between.

2.2. Statistical analysis
The sample size was calculated before starting the
study protocol with the formula described by the
PASS software table [14], and the minimum intended
sample size was determined to be 61 patients. We
performed descriptive statistical analysis in the
baseline demographic characteristics in the patients
of the study and are reported in frequencies and
percentages. The DT and HADS scores were
analyzed and reported in means and standard deviations. We compared the DT and HADS scores
with a Receiver Operating Characteristic (ROC)
analysis to obtain an optimal DT cut-off score that
distinguishes clinically signiﬁcant depression and/or
anxiety as deﬁned by HADS. The area under the
curve (AUC) was used to establish the discrimination
accuracy of the DT in neuro-oncology patients for
detection of depression and/or anxiety, deﬁned as a
HADS >14. We reported the True Positives, True
Negatives, False Positives and False Negatives for
each DT score, and calculated the sensitivity, speciﬁcity, positive and negative predictive values, positive and negative likelihood ratios, and their
respective 95% conﬁdence intervals for each possible
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DT cut-off score. Missing and indeterminate data
were excluded from the statistical analysis. To
determine the association between each of the demographic variables, clinical variables, and PL, we
performed a chi-squared analysis to categorical variables and t-test for numerical variables, signiﬁcance
was considered as a p < 0.05. Associations between
the DT and HADS scores and the PL items were
explored via Pearson's correlation coefﬁcient. The
data were made available in a data repository [15].

3. Results
3.1. Demographic description
Of the 110 patients, two were excluded because of
missing data; the ﬁnal analysis included 108 participants with brain tumors, 40 had gliomas, 31 had
pituitary adenomas, 21 had meningiomas, and 16
had other types of tumors, such as vestibular
schwannomas, brain metastases, and lymphoma.
Other demographic baseline and diagnostic characteristics can be found in Table 1.

Mean distress as measured by DT was 5.37 (SD ¼
3), and the mean total problem list score was 21 (SD
Table 1. Baseline Demographic and Diagnosis of participants in the
study.
Gender
Male
Female
Mean age in years, (Range)
Maximum Academic Level
Never Studied
Primary School
High School
College
Marital Status
Married
Single
Partnership
Widowed
Divorced
Type of Tumor
Meningioma
Gliomas
Pituitary Adenoma
Other
Tumor Lateralization
Right
Left
Other
Time From Diagnosis
<1 month
1e3 months
>3 months

¼ 9.14), with the most common subtype of problems
being physical problems (mean 7.7, SD ¼ 4.5) and
emotional problems (mean 3.8, SD ¼ 1.9). HADS-T
score mean was 13.7 (SD ¼ 7.3), with the mean
HADS-D and HADS-A subsets being 5.8 (SD ¼ 4)
and 7.85 (SD ¼ 4.4) respectively. The HADS-T scale
was positive (score>14) in 52 patients (48% of patients in the sample).
Correlation analysis comparing the DT score and
the subsets of the PL show a positive correlation for
the total number of problems (r ¼ 0.41, p < 0.001), as
well as the subsets of emotional problems (r ¼ 0.51,
p < 0.001), physical problems (r ¼ 0.26, p ¼ 0.005)
and family-related problems (r ¼ 0.2, p ¼ 0.036). A
non-signiﬁcant correlation with practical problems
(r ¼ 0.12, p ¼ 0.19) was found. DT score was not
signiﬁcantly correlated with the academic level of
the patient (r ¼ 0.066, p ¼ 0.49). Correlation analysis between the DT and HADS scores resulted in a
positive correlation (r ¼ 0.44, p < 0.001). Table 2
shows the PL's subset values and their correlation
with the DT score, as well as with the HADS score.
3.3. Receiver Operating Characteristic (ROC)
analysis

3.2. Distress measurement and correlation analysis

Patient Characteristic
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n

%

58
50
43.5 (16e72)

53.7%
46.3%

18
21
51
18

16.7%
19.4%
47.2%
16.7%

60
29
11
5
3

55.5%
26.9%
10.2%
4.6%
2.8%

21
40
31
16

19.4%
37%
28.7%
14.8%

29
40
39

26.9%
37%
36.1%

35
29
44

32.4%
26.9%
40.7%

We compared the DT score with HADS-T, taking
a score >14 as a positive test; sensitivity, speciﬁcity,
predictive values, and likelihood ratios were calculated, expressed in Table 3. Receiver Operating
Curve (ROC) analysis was performed to determine
the optimal cut-off point of the DT in our population. We obtained an Area Under the Curve (AUC)
of 0.71 (CI95% ¼ 0.61e0.81, p < 0.001) comparing
against HADS-T score, an AUC of 0.726 (CI95% ¼
0.62e0.82, p < 0.001) comparing against the HADSA subset, and an AUC of 0.63 (CI95% ¼ 0.53e0.74, p
¼ 0.021) when comparing against HADS-D subset
(Fig. 2).

4. Discussion
In this study, we validated the DT in a Mexican
population of patients with brain tumors, a population with historically high levels of distress.
Regarding demographic characteristics, our study
provides a sample size following other studies in
patients with the same pathology with roughly the
same sex distribution and marital status; however,
larger studies that use the DT exist in other more
common types of cancer [16]. Our sample's mean age
was younger than other reported series, and our time
from diagnosis was more evenly distributed between
<1 month, 1e3 months, and >3 months, which could
have contributed to their levels of distress [9,17]. We
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Table 2. Distribution of the Problem Categories and Correlation Analysis of each PL category and the DT score, as well as the HADS-T Score and the
DT Score.
Problem List Category

Mean

Standard Deviation

Correlation coefficient (r)

P value

Physical
Emotional
Practical
Family
Total Problems
HADS-T Score

7.7
3.8
2.6
0.4
21
13.7

9.14
1.9
1.4
0.7
9.1
7.3

0.26
0.51
0.12
0.2
0.41
0.44

0.005
0.001
0.19
0.036
0.001
0.001

measure the academic study level to determine its
association with levels of distress, which did not yield
a signiﬁcant correlation in the statistical analysis.
Many studies have tried to determine distress
levels in patients with brain tumors, using the DT as
a screening tool [9,17e22]. The diagnosis distribution of the different brain tumors characterizes our
series in that we included malignant and benign
tumors as well (meningiomas, pituitary adenomas)
compared to previously published series. We proceed this way because we believe that a brain tumor,
no matter the type, is a signiﬁcant source of distress
in any person; however, it is also a limitation of the
study since the DT was intended to be used in
cancer patients only. Due to this, another study,
with a sub-analysis of distress in different brain
tumors, would be useful to determine the distress
levels divided by this variable.
The prevalence of depression in brain cancer patients has been estimated to be 21.7% in a recent
meta-analysis [23]. Depression carries an inherent
risk of suicide; in cancer patients, it has been
described to increase (RR ¼ 13.6) in the ﬁrst week
after diagnosis and to persist after (3.1) the ﬁrst year
[24]. It demonstrates, once again, the importance of
correct screening and management of mental health
disorders in these patients. It has been demonstrated that preoperative depression decreases the
overall survival of patients in the ﬁrst year after
surgery (from 41% to 15%) [25].

In our study, mean distress levels were similar to
other studies done in brain cancer patients [9,17],
which range from 5.5 to 5.7, but higher than other
types of cancer, such as breast [26], gynecologic and
colorectal [27,28]. The PL sources of distress also
behaved similarly, with physical problems being the
most common source of distress [20], followed by
emotional problems. However, in our study, the
(PL) emotional problems have the highest correlation with the distress levels. In this sample, 48% of
the patients presented with a positive screening test
(using HADS), which shows that levels of depression and anxiety are higher in patients with brain
tumors than other oncologic diseases (range
25e34%), depending on the type of cancer and time
since diagnosis [21,26e28].
The main difference of all the studies in different
types of cancer is that of the optimal cut-off score of
the DT for the best sensitivity and speciﬁcity, but the
most common cut-off is 4 [16]. In our analysis, the DT
performed as a tool with moderate discrimination
abilities compared with the HADS-T (AUC ¼ 0.71),
with slightly better discrimination for anxiety than
for depression. The optimal cut-off score for a
screening test should be the one with high sensitivity,
an acceptable speciﬁcity, and the highest positive
likelihood ratio. Therefore, the best cut-off in our
sample of patients with brain tumors was 6, which
yields a sensitivity of 75% and a speciﬁcity of 70%
with a positive likelihood ratio of 2.5. The cut-off of
six is similar to other studies, and since the DT is a

Table 3. Sensitivity, Speciﬁcity, Positive and Negative Predictive Values (PPV and NPV), Positive and Negative Likelihood Ratios (LRþ, LR-) for each
cut-off point of the DT when compared to the HADS-T score as a reference standard test.
DT Cut-Off Values
DT Cut-Off TP TN FP FN Sensitivity (CI95%) Specificity (CI95%) PPV (CI95%)
value

NPV (CI95%)

LRþ (CI95%)

LR- (CI95%)

1
2
3
4
5
6
7
8
9
10

86%
79%
79%
77%
78%
75%
67%
59%
54%
52%

1.1 (1.0e1.21)
1.26 (1.06e1.5)
1.36 (1.11e1.68)
1.47 (1.15e1.87)
1.84 (1.35e2.54)
2.5 (1.61e3.79)
2.13 (1.35e3.43)
1.82 (1.03e3.23)
1.66 (0.6e4.93)
1.08 (0.28e4.09)

0.18
0.29
0.29
0.32
0.31
0.35
0.53
0.75
0.93
0.99

51
48
47
47
43
39
32
22
8
4

6
15
19
23
31
39
40
43
51
52

50
41
37
33
25
17
16
13
5
4

1
4
5
7
9
13
20
30
44
48

98% (88e99%)
92% (80e97%)
90% (78e96%)
87% (73e94%)
83% (69e91%)
75% (60e85%)
62% (47e74%)
42% (29e56%)
15% (7e28%)
8% (2e18%)

11%
27%
34%
41%
55%
70%
71%
77%
91%
93%

(4e22%)
(16e40%)
(22e48%)
(28e55%)
(41e68%)
(55e80%)
(57e82%)
(62e86%)
(80e96%)
(80e97%)

50%
54%
56%
58%
63%
70%
67%
63%
62%
50%

(40e60%)
(43e64%)
(44e66%)
(45e68%)
(50e74%)
(56e81%)
(51e79%)
(45e78%)
(32e84%)
(17e82%)

(42e99%)
(53e93%)
(57e92%)
(57e89%)
(61e88%)
(60e85%)
(53e78%)
(47e70%)
(43e64%)
(38e58%)

(0.02e1.44)
(0.1e0.81)
(0.11e0.7)
(0.15e0.7)
(0.17e0.59)
(0.22e0.59)
(0.37e0.79)
(0.57e0.99)
(0.81e1.07)
(0.89e1.11)
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Fig. 2. ROC Curves comparing the DT Scores with the HADS Total Score with its Anxiety and Depression subscales.

screening test, we consider it to be the optimal score
to use in patients with brain tumors.
In brain tumors, sometimes, there is a belief that
these tools can be ineffective due to the cognitive
and functional damage that neurological conditions
cause in the patients; however, in several studies
with brain tumors, the DT has been correctly validated. Moreover, a higher risk for mental health
conditions has been described due to the risk of
functional, neurologic, and cognitive sequelae that
can result from brain cancer [20], concordant with
the results of the present study.
The NCCN deﬁnes distress as a “multifactorial,
unpleasant experience of a psychological (i.e.,
cognitive, behavioral, emotional), social, spiritual,
and/or physical nature that may interfere with the
ability to cope effectively with cancer, its physical
symptoms, and its treatment” [4]. In Mexico, and the
Spanish language overall population, there is a
common misunderstanding and misuse of the word
distress, since there exists no word in Spanish that
correctly translates distress. Therefore, it has been
used as a word to describe a combination of

depression and anxiety, but these words are not the
same as the deﬁnition of distress in English. We
found the DT and HADS scores have a signiﬁcant but
moderate correlation coefﬁcient, probably explaining they measure different concepts (as referred
above), the one being depression or anxiety, and the
other being distress. This fact provides a clue for
many other factors that may have a signiﬁcant effect
on brain tumors' emotional complications.

5. Limitations
One of the main limitations of our study is the
relatively small sample size. We included tumors of
different lineages, which can make more challenging
the interpretation of the results. Single-lineage
studies will have to be done in future research.

6. Clinical implications
This study may help to encourage the use of tools
such as the distress thermometer in patients with
brain tumors. We generally focus on assessing their
neurological and functional status, but we neglect the

DAN MORGENSTERN-KAPLAN ET AL
VALIDATION OF THE DISTRESS THERMOMETER IN A MEXICAN POPULATION WITH BRAIN TUMORS

implications in their emotions, which are of utmost
importance.

7. Conclusions
The DT is a psycho-oncologic screening tool that
is applied to cancer patients to screen for emotional
distress and is accompanied by the PL checklist for
the patient to ﬁll out the sources of that distress. We
used it in patients with intracranial tumors and
found out six as a good cut-off point. Larger studies
are needed in order to analyze separately between
malignant and benign tumors.
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The authors are making the ﬁrst approach to
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As they state in their work, any kind of brain tumor,
regardless of whether it has or not an aggressive
behavior, could be a source of distress. Moreover, to
have this instrument in the armamentarium to
evaluate the emotional status of the Mexican
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population will be a useful tool to make psychological interventions that help the patients improve
their prognosis and quality of life, and also their
adherence to treatment. The authors found that,
even though the DT has been validated for oncologic pathologies, brain tumor patients showed a
higher percentage of positive screening tests, and
this ﬁnding enforces the necessity of this kind of
instrument to evaluate mental health disorders in
neuro-oncologic patients.
Barbara Nettel Rueda, MD
Specialties Hospital, National Medical Center Century
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